- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03485560
Revitalization of Damaged Skin Due to Chronic Skin Diseases
Revitalization of Damaged Sking Due to Chronic Skin Diseases
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Psoriasis is a chronic, immune mediated (type 2 and type 17) chronic skin disease. The production of the immune proteins that leads to continuous inflammatory mediated process. The result of chronic inflammation is they hyper keratotic layer of skin which gets attacks of atopic dermatitis leading to symptoms of itching, pruritis and in situ bleeding.
ACE CSD, with the multiple factors that mediates the immune response and control the protein receptors, in addition to the multiple regeneration peptides that are specifically extracted from healthy skin of newly born sheep; in addition to multiple Chinese herbs that contains different anabolic factors was tested to be able to regenerate the damaged skin and locally modulate the immunity reactions so the skin can regenerate fully to replace the damaged skin with normal healthy skin.
Study Type
Enrollment (Anticipated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Dr. Alaa Abdelkarim MF Mohammed
- Phone Number: +447473922553
- Email: dralaakarim@gmail.com
Study Contact Backup
- Name: Dr. Diana Diana, MsC dermatology
- Email: dr.dianadiana@outlook.com
Study Locations
-
-
-
Belgrade, Serbia, 11000
- ACE cells Lab Europe Doo
-
Contact:
- Dr. Diana Diana, MsC dermatology
- Email: dr.dianadiana@outlook.com
-
-
-
-
Nottinghamshire
-
Nottingham, Nottinghamshire, United Kingdom, NG90 6BH
- ACE Cells Lab Limited
-
Contact:
- Dr. Alaa Abdelkarim MF Mohammed, Consultant
- Phone Number: 7473922553
- Email: dralaakarim@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Chronic skin condition lasts for more than 1 year.
- tried traditional treatment with limited or without effect.
- not on steroids for at least 6 weeks.
Exclusion Criteria:
- patients on steroid.
- patients intolerable to protein or allergic to proteins
- during pregnancy or lactation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: internvention of Chrinic skin conditions
All cases of chronic skin conditions will be included to measure the effect on the 3 of them and whihc one will respond to the treatment better
|
Topical application of the ACE CSD 4 times daily.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Regeneration of the damaged skin lesion
Time Frame: 6 - 9 months
|
Complete regeneration of the affected skin lesions from the skin disease.
|
6 - 9 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Flare control
Time Frame: 1-3 months
|
During the attacks of flare, the regenerated skin does not get affected nor show erythematous reaction
|
1-3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dr. Diana Diana, MSc Dermatology, ACE cells Lab Europe Doo
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ACEcsd
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriasis
-
ProgenaBiomeRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Face | Psoriasis Nail | Psoriasis Diffusa | Psoriasis Punctata | Psoriasis Palmaris | Psoriasis Circinata | Psoriasis Annularis | Psoriasis Genital | Psoriasis GeographicaUnited States
-
Clin4allRecruitingPsoriasis of Scalp | Psoriasis Nail | Psoriasis Palmaris | Psoriasis Genital | Psoriasis PlantarisFrance
-
Innovaderm Research Inc.CompletedScalp Psoriasis | Pustular Palmo-plantar Psoriasis | Non-pustular Palmo-plantar Psoriasis | Elbow Psoriasis | Lower Leg PsoriasisCanada
-
Centre of Evidence of the French Society of DermatologyRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Palmaris | Psoriatic Erythroderma | Psoriatic Nail | Psoriasis Guttate | Psoriasis Inverse | Psoriasis PustularFrance
-
UCB Biopharma S.P.R.L.CompletedModerate to Severe Psoriasis | Generalized Pustular Psoriasis and Erythrodermic PsoriasisJapan
-
AmgenCompletedPsoriasis-Type Psoriasis | Plaque-Type PsoriasisUnited States
-
TakedaRecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Janssen Pharmaceutical K.K.RecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Eli Lilly and CompanyCompletedGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Shanghai Huaota Biopharmaceutical Co., Ltd.RecruitingGeneralized Pustular Psoriasis (GPP)China
Clinical Trials on ACE CSD
-
Acorn Cardiovascular, Inc.UnknownHeart FailureUnited States, Canada
-
PepsiCo Global R&DTerminatedSweetness Liking AdaptationUnited States
-
PepsiCo Global R&DCompletedSweetness Liking AdaptationUnited States
-
CelgeneTerminatedBeta Thalassemia Intermedia | Beta Thalassemia MajorFrance, United Kingdom, Italy, Greece
-
PepsiCo Global R&DCompletedSweetness Liking AdaptationMexico
-
Acceleron Pharma Inc. (a wholly owned subsidiary...TerminatedFacioscapulohumeral Muscular DystrophyUnited States, Spain, Canada
-
University of Alabama at BirminghamACE Surgical Supply, Inc.Completed
-
Megadyne Medical Products Inc.UnknownAbdominoplasty | Bilateral Breast Reduction | Bilateral Breast Lift | Bilateral Brachioplasty | Bilateral Lateral Thigh and Buttocks LiftUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedSotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or AnemiaAnemia | Myelofibrosis | Myelodysplastic/Myeloproliferative NeoplasmUnited States
-
University of AlbertaCompletedCoronary Artery DiseaseCanada